These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34827122)

  • 1. Association between Sleep, Alzheimer's, and Parkinson's Disease.
    Matsumoto S; Tsunematsu T
    Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
    Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
    IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?
    Marwarha G; Ghribi O
    Exp Gerontol; 2015 Aug; 68():13-8. PubMed ID: 25261765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease.
    Casciano F; Zauli E; Celeghini C; Caruso L; Gonelli A; Zauli G; Pignatelli A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
    Irwin DJ; Hurtig HI
    J Alzheimers Dis Parkinsonism; 2018; 8(4):. PubMed ID: 30473927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could exercise hormone irisin be a therapeutic agent against Parkinson's and other neurodegenerative diseases?
    Avgerinos KI; Liu J; Dalamaga M
    Metabol Open; 2023 Mar; 17():100233. PubMed ID: 36785617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation.
    Shim KH; Kang MJ; Suh JW; Pyun JM; Ryoo N; Park YH; Youn YC; Jang JW; Jeong JH; Park KW; Choi SH; Suk K; Lee HW; Ko PW; Lee CN; Lim TS; An SSA; Kim S;
    Alzheimers Res Ther; 2020 Jul; 12(1):83. PubMed ID: 32660565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.
    Chiu PY; Yang FC; Chiu MJ; Lin WC; Lu CH; Yang SY
    Sci Rep; 2022 Oct; 12(1):17919. PubMed ID: 36289355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson's Disease.
    Scott-Massey A; Boag MK; Magnier A; Bispo DPCF; Khoo TK; Pountney DL
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease.
    Gutierrez BA; Limon A
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease.
    Du L; He X; Fan X; Wei X; Xu L; Liang T; Wang C; Ke Y; Yung WH
    Pharmacol Ther; 2023 Sep; 249():108498. PubMed ID: 37499913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.
    Bonanni L; Thomas A; Tiraboschi P; Perfetti B; Varanese S; Onofrj M
    Brain; 2008 Mar; 131(Pt 3):690-705. PubMed ID: 18202105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.